![](/img/cover-not-exists.png)
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial
Dytfeld, Dominik, Griffith, Kent A., Friedman, Judah, Lebovic, Daniel, Harvey, Colleen, Kaminski, Mark S., Jakubowiak, Andrzej J.Volume:
52
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2011.567316
Date:
July, 2011
File:
PDF, 618 KB
english, 2011